Genome & Company (KOSDAQ: 314130)
South Korea
· Delayed Price · Currency is KRW 2,770.00
-125.00 (-4.32%)
Dec 19, 2024, 2:34 PM KST
Genome & Company Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Net Income | -35,671 | -47,466 | -51,838 | -34,117 | -30,732 | -84,669 |
| Depreciation & Amortization | 7,778 | 8,272 | 9,462 | 2,591 | 1,464 | 570.03 |
| Loss (Gain) From Sale of Assets | 145.21 | 77.11 | -0.69 | 12.93 | 92.58 | - |
| Asset Writedown & Restructuring Costs | 2,325 | 2,325 | - | - | - | - |
| Loss (Gain) From Sale of Investments | -101.6 | -46.44 | - | - | - | - |
| Stock-Based Compensation | 10,687 | 12,066 | 6,083 | 5,566 | 6,753 | 2,680 |
| Provision & Write-off of Bad Debts | - | - | -12.92 | - | - | - |
| Other Operating Activities | -1,877 | -4,648 | -3,864 | -1,658 | 4,592 | 70,891 |
| Change in Accounts Receivable | -258.76 | 1,126 | -1,145 | 11.95 | - | - |
| Change in Inventory | -2,622 | -1,694 | -886.4 | -154.36 | - | - |
| Change in Accounts Payable | -59.04 | 132.77 | -139.79 | 14.8 | - | - |
| Change in Other Net Operating Assets | 641.94 | -2,368 | -1,209 | 1,573 | -326.66 | 478.59 |
| Operating Cash Flow | -19,013 | -32,224 | -43,550 | -26,159 | -18,157 | -10,048 |
| Capital Expenditures | -6,899 | -18,853 | -6,849 | -2,875 | -1,504 | -687.55 |
| Sale of Property, Plant & Equipment | -4.69 | - | 0.96 | 0.5 | 0.5 | - |
| Cash Acquisitions | - | - | - | -26,721 | - | - |
| Divestitures | - | - | - | - | 289.69 | - |
| Sale (Purchase) of Intangibles | -263.79 | -189.09 | -427.29 | -504.78 | -325.02 | -307.21 |
| Investment in Securities | 9,787 | 4,742 | 7,453 | -29,609 | 3,045 | -3,645 |
| Other Investing Activities | -119.18 | -1,129 | -99.49 | -100.48 | 673.23 | 51.78 |
| Investing Cash Flow | 2,500 | -15,430 | 77.52 | -59,810 | 2,179 | -4,588 |
| Long-Term Debt Issued | - | 32,509 | - | - | - | - |
| Long-Term Debt Repaid | - | -2,023 | -1,645 | -820.29 | -428.51 | -158.96 |
| Net Debt Issued (Repaid) | 4,587 | 30,487 | -1,645 | -820.29 | -428.51 | -158.96 |
| Issuance of Common Stock | 26.42 | 81.49 | 126.83 | 1,248 | 71,450 | 211.84 |
| Other Financing Activities | -46.18 | - | 35.61 | 57.69 | 0 | 0 |
| Financing Cash Flow | 4,567 | 30,568 | 78,550 | 17,617 | 98,633 | 30,244 |
| Foreign Exchange Rate Adjustments | -334.82 | 1,226 | 1,089 | 453.3 | -646.07 | -2.06 |
| Miscellaneous Cash Flow Adjustments | -0 | -0 | 0 | -0 | 0 | 0 |
| Net Cash Flow | -12,280 | -15,860 | 36,167 | -67,898 | 82,010 | 15,605 |
| Free Cash Flow | -25,912 | -51,077 | -50,399 | -29,034 | -19,662 | -10,736 |
| Free Cash Flow Margin | -107.56% | -357.28% | -357.83% | -6434.20% | -13057.09% | -23423.41% |
| Free Cash Flow Per Share | -1248.28 | -1808.70 | -1790.39 | -1080.03 | -1021.03 | -669.65 |
| Cash Interest Paid | 636.65 | 310.78 | 170.8 | 52.71 | 48.13 | 10.43 |
| Cash Income Tax Paid | 130.26 | 92.92 | 54.31 | 10.84 | 8.7 | 4.49 |
| Levered Free Cash Flow | -24,364 | -31,457 | -35,323 | -17,129 | -76,734 | - |
| Unlevered Free Cash Flow | -22,375 | -30,371 | -35,213 | -17,095 | -75,961 | - |
| Change in Net Working Capital | 7,427 | -5,495 | 4,722 | -2,893 | 64,054 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.